Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
A Licensing Agreement Won't Protect This Biotech From A Takeover | Investor's Business Daily
UBS Has Nine Biotech Buyout and Merger Candidates – 24/7 Wall St.
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma and CANBridge cancel licensing deal for $20m
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma pounces on failed Takeda drug, snapping up cancer prospect
Puma Shares Soar 81% Over 2 Days - Los Angeles Business Journal
Is Puma Biotechnology a Buy? | The Motley Fool
Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
Why Puma Biotech Could Get Acquired Between July to September of This Year | BioSpace
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib | Nasdaq
5 Best Biotech Stocks for 2018 | InvestorPlace
Puma Biotech punts near $300 million on Takeda discard
10 Takeover Targets of 2018
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? (NASDAQ:PBYI) | Seeking Alpha
